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Abstract
Introduction: Corneal collagen cross-linking is a rather new technique that uses riboflavin and ultraviolet A light
for collagen fiber stabilization in keratoconus corneas. Other than reversible side effects, the preliminary results of
corneal collagen cross-linking studies suggest that it is a rather safe technique. In this report, we demonstrate a
case of corneal melting after corneal collagen cross-linking for keratoconus corneas associated with an acute
inflammatory response.
Case presentation: A 23-year-old Caucasian man with keratoconus cornea stage 1 to 2 underwent uneventful
corneal collagen cross-linking treatment according to the Dresden protocol. The next day the patient had intense
photophobia, watering and redness of the eye, and his visual acuity was limited to counting fingers. Slit lamp
biomicroscopy revealed severe corneal haze accompanied by non-specific endothelial precipitates following an
acute inflammatory response. Mild inflammation could be detected in the anterior chamber. Moreover, the re-
epithelialization process could barely be detected. His corneal state gradually deteriorated, resulting in
descemetocele and finally perforation.
Conclusion: In this report, we present a case of a patient with corneal melting after standard corneal collagen
cross-linking treatment for keratoconus corneas following an acute inflammatory response. Despite modifying
postoperative treatment, elaboration of all apparent associated causes by the treating physicians and undergoing
extensive laboratory testing, the patient developed descemetocele, which led to perforation. Our report suggests
that further research is necessary regarding the safety of corneal collagen cross-linking in keratoconus corneas.
Introduction
Keratoconus (KC) is a degenerative non-inflammatory cor-
neal disease. It is usually bilateral and has an incidence of
approximately one per 2000 in the general population
[1,2]. In the majority of cases, KC starts at puberty and
progresses at a variable rate [2]. Eventually, about 20% of
KC eyes require penetrating keratoplasty [3]. Corneal col-
lagen cross-linking (CXL) is a rather new therapeutic
approach attempting to address KC progression by using
riboflavin and ultraviolet A (UVA) radiation. The primary
objective of CXL is to stabilize the collagen fiber matrix in
KC corneas [4,5]. Beyond reversible side effects that are
mainly associated with postoperative infections, prelimin-
ary results of CXL studies suggest that it is a rather safe
technique [6,7]. Therefore, recent publications indicate
that CXL might be used as a therapeutic alternative in a
series of other corneal diseases such as infectious keratitis
and corneal bullosa [8,9]. Within this context, we present
a case report regarding corneal melting after CXL with
riboflavin and UVA for KC that eventually required pene-
trating keratoplasty because of perforation.
Case presentation
An otherwise healthy 23-year-old Caucasian man was
referred to our institute as a potential candidate for
CXL. According to his referral documents, the patient
had an uneventful medical history, and despite progres-
sive bilateral keratoconus he had no other ophthalmolo-
gical problems. However, during the past year, he had
developed contact lens intolerance.
At presentation, his uncorrected visual acuities were
0.4 logMar and 0.5 logMar in his right and left eyes,
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were 0.1 logMar (-0.25 spherical (SPH), -2.50 cylindrical
(CYL) × 20) in his right eye and 0.3 logMar (-0.50 SPH,
-3.00 CYL × 155) in his left eye. Central corneal pachy-
metry measured with a Scheimpflug camera (Pentacam
Oculyzer; Oculus Optikgerate GmbH, Heidelberg, Ger-
many) was 462 μma n d4 5 5μm in his right and left
eyes, respectively. The thickness of the thinnest corneal
point (TCT) in the left eye was 443 μm (Figure 1), while
the keratometric readings derived from the Pentacam
test were K1-43.1, K2-46.4 in the right eye and K1-43.2,
K2-46.6 in the left eye, respectively. In comparison to
the patient’s referral documents, within the past year the
patient had demonstrated deterioration in his BCVA
(former BCVA 0.2 logMar (-0.50 SPH, -2.25 CYL × 155)
and in the TCT (former TCT was 449 μm). According
to the topographical keratometric data, he was diag-
nosed with KC stage 1 or 2 and scheduled for CXL
therapy.
Standard CXL treatment was performed in the
patient’s left eye according to the following procedure:
Alcaine drops were used for topical anesthesia, followed
by application of a sponge saturated with 20% alcohol
to the central cornea for 15 seconds. De-epithelializa-
tion was performed by means of a hockey knife. The
residual corneal thickness after debridement was 407
μm as measured by ultrasound contact pachymetry
(Pacline; Optikon 2000 SpA, Rome, Italy). After de-
epithelialization, a mixture of 0.1% riboflavin in 20%
dextran solution was instilled into the cornea for 30
minutes (two drops every two minutes) until the stroma
was completely penetrated and the aqueous humor was
stained yellow. Regarding the UVA radiation source, the
UV-X system (Peschke Meditrade GmbH, Cham, Swit-
zerland) was employed. An 8.0 mm diameter of the
central cornea was irradiated for 30 minutes by UVA
light with a wavelength of 370 nm and at surface radi-
ance of 3 mW/cm
2, which corresponds to a surface
dose of 5.4 J/cm
2. It should be mentioned that the use
of riboflavin was continued during irradiation to main-
tain the necessary concentration. Moreover, balanced
salt solution was applied every six minutes to moisten
the cornea. When the irradiation was complete, a soft
contact lens (Day & Night; CIBA Vision, Duluth, GA,
USA) was applied until full re-epithelialization was
completed.
Figure 1 Preoperative Pentacam Oculyzer image of the patient’s left eye.
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tive medications: (1) gentamicin sulfate and dexametha-
sone dihydrogenophosphate drops (Dexamytrex
Ophtiole; Bausch & Lomb, Berlin, Germany) four times
daily and (2) a monodose combination of sodium hya-
luronate 0.15% and dexpanthenol 2% (HyloPan; Zwitter-
Pharmaceuticals, Halandri, Greece) every hour.
Despite an uneventful CXL treatment, during the first
postoperative day the patient developed intense photo-
phobia, watering and a non-specific ocular discomfort.
Slit lamp biomicroscopy revealed redness, especially at
the limbal region, severe corneal haze accompanied by
non-specific endothelial precipitates and a few inflamma-
tory cells in the anterior chamber (Tyndall effect +1)
(Figure 2). The aforementioned findings resembled an
acute inflammatory response to the CXL procedure and/
or possibly to the postoperative medication. Moreover,
no evidence of re-epithelialization was observed, and the
patient’s visual acuity was limited to counting fingers.
The patient’s postoperative medication was modified
to ofloxacin drops four times per day quid (Exocin;
Allergan, Castlebar Road, Westport, CoMayo, Ireland),
dexamethasone drops every two hours (Maxidex; Alcon
Cusi, SA, Spain), frequent use of carboxymethylcellulose
0.5% drops (Optive; Allergan, Irvine, Ca) and oral acy-
clovir 400 mg four times daily (Zovirax; GlaxoSmithk-
line, Aranda, Spain). Further to the postoperative
regimen change, the patient underwent a complete
laboratory examination for autoimmune and infectious
diseases, including markers for rheumatoid factor,
immune complexes, C-reactive protein, antineutrophilic
cytoplasmic antibodies and erythrocyte sedimentation
rate, as well as polymerase chain reaction for herpes
simplex virus DNA detection, which were all negative or
within normal limits. Moreover, repeated cultures from
cornea samples and the contact lens were all negative.
However, the patient was evaluated for hypersensitivity
to riboflavin (vitamin B2) and other components of the
B vitamin complex as well as a series of common aller-
gens. According to the results presented in Table 1, no
evidence of a hypersensitivity reaction could be detected.
The treatment change resulted in subjective improve-
ment of ocular discomfort and disappearance of the
inflammatory cells in the anterior chamber. However,
the cornea presented extremely slow re-epithelialization
and progressive thinning, which resulted in descemeto-
cele and finally perforation in the second postoperative
month. The patient underwent uncomplicated penetrat-
ing keratoplasty with an uneventful postoperative period.
Discussion
Corneal CXL has gained popularity as a temporary
block in the progression of keratoconus. Preliminary
results published in the literature indicate that when a
series of safety precautions are taken, the technique has
an excellent safety profile. These prerequisites are (1)
de-epithelialization of the cornea to facilitate the absorp-
tion of riboflavin, (2) use of riboflavin 0.1% for at least
30 minutes, (3) homogeneous UV irradiation and (4) a
minimal central corneal thickness of 400 μm [10]. All of
the aforementioned criteria were met in our case.
An extensive literature search retrieved the following
cases of CXL melting. Gokhale et al. [11] recently pre-
sented a case of acute corneal melting after CXL for
keratoconus which was attributed to the hazardous
impact of diclofenac on stromal keratocytes. Despite the
fact that no apparent etiologic relationship between
non-steroidal anti-inflammatory drugs (NSAIDs) and
corneal melting has been demonstrated in the literature,
several investigators have attempted to associate kerato-
lysis with postoperative NSAID therapy [12]. The poten-
tial impact of NSAIDs on keratocytes is well known to
the authors, thus we did not use NSAIDs as standard
postoperative treatment in CXL. Furthermore, Faschin-
ger et al. [13] reported a case of bilateral melting after
Figure 2 Slit lamp biomicroscopic image showing severe
corneal haze and endothelial precipitates due to the acute
inflammatory response.
Table 1 Patient’s serum allergen values
a
RAST test Immunoglobulin E
level, U/mL
Vitamin B1 0.13 (negative)
Vitamin B2 0.16 (negative)
Vitamin B12 0.18 (negative)
Dermatophagoides pteronyssinus 0.09 (negative)
Dermatophagoides farina 0.08 (negative)
Erect pellitory-of-the-wall
(Parietaria officinalis)
0.09 (negative)
aRAST test, radioallergosorbent test. (Levels 0-0.35 U/mL negative, 0.35-0.70 U/
mL low possibility for allergy, 0.70-3.50 U/mL positive with low
immunoglobulin E levels, 3.50-17.50 positive with high immunoglobulin E
levels,17.50-52.50 positive with very high immunoglobulin E levels.)
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however, the required minimal stromal thickness of 400
μm was not met.
According to our pachymetric data, neither the central
corneal thickness nor the thinnest corneal thickness was
below 400 μm in our patient. On the other hand, Angu-
nawela et al. [14] presented a case of sterile corneal
infiltrates and melting after CXL for keratoconus. They
attempted to associate their findings with enhanced cell-
mediated immunity to staphylococcal antigens deposited
at high concentrations in areas with static tear pooling
beneath the bandage contact lens. However, the corneal
infiltrations were detected five days postoperatively
under an intact epithelium. No evidence of non-infective
keratitis could be demonstrated in our case. Regarding
post-CXL haze, Raiskup et al. [15] reported in their ret-
rospective survey that 8.6% of the KC eyes that under-
went CXL treatment developed clinically significant
permanent stromal haze. However, no associations with
increased risk for corneal melting were described.
Concerning potential anaphylaxis with riboflavin, the
literature suggests that it is well tolerated even at high
doses, and only one documented case of anaphylaxis
after oral administration of riboflavin was retrieved [16].
In our patient, no indications of hypersensitivity to ribo-
flavin could be identified.
It is well known that during CXL treatment the kerato-
cytes suffer significant damage because of UV radiation
and the generation of oxygen and superoxide radicals
[17]. However, the literature suggests that this cell apop-
tosis is reversible and that the affected area is repopu-
lated within six months [18]. Moreover, because of the
shielding effect of riboflavin, the standard CXL procedure
seems to cause no damage to the endothelial cells.
Conclusion
Despite the aforementioned data from other clinical and
research settings, the CXL procedure caused non-speci-
fic irreversible damage to keratocytes in our patient that
cannot be directly attributed to postoperative treatment
or to cell-mediated immunity to antigens. Moreover, no
evidence of underlying autoimmune disease or local
infection could be detected. The exact cause of corneal
melting in our case remains unknown to us. An immu-
nohistochemical examination of the affected cornea
could provide more data regarding its pathological
mechanism. Nevertheless, since all precautions for stan-
dard CXL treatment were met in our case, further
research is necessary to address all safety issues asso-
ciated with this procedure.
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